Treatment Approach for Functional Hypothalamic Amenorrhea

Priority: Non-Pharmacological Treatment Must Continue

The primary treatment for Functional Hypothalamic Amenorrhea (FHA) remains continued non-pharmacological intervention, including maintaining adequate energy availability, moderate exercise, and stress reduction, while letrozole can be used for ovulation induction if pregnancy is desired, according to the British Journal of Sports Medicine 1, 2, 3
The goal of exercise modification is to achieve positive energy balance, not eliminate physical activity, as recommended by the British Journal of Sports Medicine 1, 2

Letrozole is appropriate for ovulation induction when pregnancy is the immediate goal, but it does not treat the underlying condition, as stated by Praxis Medical Insights: Practical Summaries of Clinical Guidelines 4
Letrozole only induces ovulation; it does not restore spontaneous hypothalamic function or normalize the metabolic derangements of FHA, according to the British Journal of Sports Medicine 1, 2, 3
Monitor endometrial thickness via transvaginal ultrasound, targeting at least 7-8mm at ovulation for optimal implantation, as recommended by Praxis Medical Insights: Practical Summaries of Clinical Guidelines 4

Combined oral contraceptives should NOT be used in women with FHA, as they create a false sense of security with withdrawal bleeding but do not restore spontaneous menses and may actually worsen bone health, according to the British Journal of Sports Medicine 1, 2, 3
The 2014 Female Athlete Triad Coalition consensus strongly emphasizes that COCs suppress hepatic IGF-1 production, further reducing this already-low bone trophic hormone in FHA, as reported by the British Journal of Sports Medicine 1, 2

Obtain baseline bone mineral density via DEXA scan, as FHA is associated with 2-fold increased fracture risk, according to Human Reproduction Update 5
FHA patients demonstrate endothelial dysfunction and increased cardiovascular risk despite normal weight, as reported by Human Reproduction Update 5

Pulsatile GnRH therapy directly addresses the underlying GnRH pulsatility defect in FHA, as stated by Praxis Medical Insights: Practical Summaries of Clinical Guidelines 4

Do not restart combined oral contraceptives, as they mask the underlying FHA, according to the British Journal of Sports Medicine 1, 2, 3
Do not rely solely on letrozole to manage FHA—it induces ovulation but does not reverse the metabolic, bone, or cardiovascular consequences of FHA, as reported by the British Journal of Sports Medicine 1, 2, 3

Continue current lifestyle modifications for at least 6 months before considering additional interventions, as recommended by the British Journal of Sports Medicine 1
If spontaneous menses do not resume after 6 months of adequate energy availability, reassess for bone density concerns and consider pulsatile GnRH if pregnancy is desired, according to Human Reproduction Update 5